← Back to all trials
Recruiting
NCT05662085
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Conditions: Pseudoxanthoma Elasticum
Sex: All
Ages: 18 Years – N/A
Enrollment: 40
Sponsor: Institute of Molecular and Clinical Ophthalmology Basel
Location: Switzerland
Summary
This study aims to systematically assess the retest reliability and ability to detect a change of new visual function tests and ophthalmological imaging methods for observing the natural course of pseudoxanthoma elasticum (PXE).
Eligibility Criteria
Inclusion Criteria:Adult patients with Pseudoxanthoma elasticum according to the Plomp criteria or adult patients with a PXE-mimicking phenotype (angioid streaks and peau d'orange [e.g., ENPP1 or GGCX-associated disease])Best-corrected visual acuity (BCVA): ≤1.0 LogMARExclusion Criteria:Inability to give informed consentClaustrophobiaPrior surgery (other than anti-VEGF injections, cataract surgery, YAG laser capsulotomy, or laser retinopexy) that - according to the investigator's judgment - may affect visual function assessments (e.g., retinal detachment surgery, glaucoma filtration surgery, or a history of a corneal transplant in the study-eye)Concurrent ophthalmic conditions in the study eye that (according to the investigator's judgment) may contribute to loss of vision, such as clinically significant opacification of the ocular media (corneal dystrophies, cataract), other retinal diseases, or disease of the optic nerve head and visual pathway (including amblyopia)Major surgery planned or other events that (according to the investigator's judgment) could hinder follow-up examinations (e.g., knee replacement)
Source: ClinicalTrials.gov (NCT05662085). StuddyBuddy aggregates publicly available trial information.